

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: A mixed-methods study

| Journal: | BMJ Open |
|-------------------------------|---|
| Manuscript ID | bmjopen-2021-052432 |
| Article Type: | Original research |
| Date Submitted by the Author: | 19-Apr-2021 |
| Complete List of Authors: | Dereje, Nebiyu; MyungSung Medical College, Department of Public Health Tesfaye, Abigel; MyungSung Medical College, Department of Medicine Tamene, Beamlak; MyungSung Medical College, Department of Medicine Alemeshet, Dina; MyungSung Medical College, Department of Medicine Abe, Haymanot; MyungSung Medical College, Department of Medicine Tesfa, Nathnael; MyungSung Medical College, Department of Medicine Gedion, Saron; MyungSung Medical College, Department of Medicine Biruk, Tigist; MyungSung Medical College, Department of Medicine Lakew, Yabets; MyungSung Medical College, Department of Medicine |
| Keywords: | COVID-19, Public health < INFECTIOUS DISEASES, EPIDEMIOLOGY |
| | |





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| 2 | |
|----------|--|
| 3 | |
| Δ | |
| 5 | |
| ر ح | |
| 0 | |
| / | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 10 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 2⊿ | |
| 24 25 | |
| 20 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | |
| 34 | |
| 35 | |
| 36 | |
| 20 | |
| 3/ | |
| 38 | |
| 39 | |
| 40 | |
| 41 | |
| 42 | |
| 43 | |
| 44 | |
| 45 | |
| 46 | |
| 17 | |
| 47 | |
| 40 | |
| 49 | |
| 50 | |
| 51 | |
| 52 | |
| 53 | |
| 54 | |
| 55 | |
| 56 | |
| 57 | |
| 57 | |
| 20 | |
| 59 | |
| 60 | |

11

1

COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: A mixed-methods study 1

- Nebiyu Dereje1*, Abigel Tesfaye2, Beamlak Tamene2, Dina Alemeshet2, Haymanot Abe2, 2
- Nathnael Tesfa², Saron Gedion², Tigist Biruk², Yabets Lakew² 3
- ¹Department of Public Health, Myungsung Medical College, Addis Ababa, Ethiopia 4
- ²Department of Medicine, Myungsung Medical College, Addis Ababa, Ethiopia 5
- *Corresponding author contact information 6
- Nebiyu Dereje 7
- Email: neba.jahovy@gmail.com 8
- P.O.Box 14972 9
- Addis Ababa, Ethiopia 10

12 Abstract

Objective: Data on COVID-19 vaccine hesitancy is limited in Ethiopia and other parts of
Africa. Therefore, the aim of this study was to determine the level of COVID-19 vaccine
hesitancy and its associated factors in Addis Ababa, Ethiopia.

Design: A community-based concurrent mixed-methods study

17 Setting: In a community setting

Participants: Adult residents (n = 422) of Akaki Kality sub-city who were recruited by a multistage sampling technique were included for the quantitative part of the study and 24 adults who
were included purposively for the qualitative in-depth interview.

Outcome Measures: Data was collected by face-to-face interview by using a semi-structured
 questionnaire. Factors associated with COVID-19 vaccine hesitancy were identified by
 multivariable binary logistic regression model, as expressed by adjusted odds ratio (aOR).

Results: One out five (19.1%) participants was not willing to get vaccinated. In the multivariable analysis, vaccine hesitancy was significantly associated with being female (aOR=1.97; 95% CI: 1.10 - 3.89), negative attitude towards COVID-19 and its preventive measures (aOR=1.75; 95% CI: 1.08 - 3.02), and primary information source being social media (internet) (aOR=3.59; 95% CI: 1.75 - 7.37). Study participants have stated that they did not have enough information about the vaccine, feared it would not be effective or have too many side effects, and reflected their uncertainty towards the quality of the vaccine.

| 3 |
|-----------|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 12 |
| 1/ |
| 15 |
| 16 |
| 10 |
| 10 |
| 10 |
| 19 |
| 20 21 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |
| 26 |
| 27 |
| 28 |
| 29 |
| 30 |
| 31 |
| 32 |
| 33 |
| 34 |
| 35 |
| 36 |
| 37 |
| 38 |
| 39 |
| 40 |
| 41 |
| 42 |
| 43 |
| 44 |
| 45 |
| 46 |
| 40 17 |
| 47 10 |
| -10 /0 |
| 49 50 |
| 50 |
| ט די |
| 52 52 |
| 55 |
| 54 55 |
| 55 |
| 56 |
| 5/ |
| 58 |
| 59 |
| 60 |

1 2

Conclusions: A considerable proportion of the people in Addis Ababa have concerns on 31 COVID-19 vaccine and unwilling to accept. This was mainly due to the misconceptions 32 distributed from the use of social media as source of information. Providing the community 33 with health education and consistent efforts to enhance the prevention measures are important, 34 particularly using different medias including social-medias. 35 **Key Words**: COVID-19, knowledge, attitude, Vaccine, Hesitancy 36 **Article Summary** 37 Strengths and limitations of this study 38 This is the first study from Ethiopia to determine the level of COVID-19 vaccine 39 hesitancy in the general population. 40 A mixed-methods approach allows for triangulation of findings from different 41 42 perspectives. The study might be limited due to the recall bias and social desirability bias during the 43 data collection. 44 **Funding statement** 45 46 This study was funded by Myungsung Medical College. However, the funder had no role in the 47 design, conduct, analysis and interpretation of this study. **Conflict of interest** 48 The authors declare that they have no conflict of interests. 49 Word count =2805 50 51 3

BMJ Open

Introduction

Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) also known as Novel coronavirus (nCov) [1]. The first case of COVID-19 was discovered in Wuhan city, Hubei province of China with unexplained pneumonia on December 12, 2019 [2]. The virus is transmitted through large droplets generated during coughing or sneezing of symptomatic and asymptomatic patients [3]. Therefore, frequent hand-washing with soap and water, using alcohol based hand rub or sanitizer, avoidance of hand shaking/public gathering and use of face mask are crucial to halt the spread of COVID-19 [4]. COVID-19 was declared a pandemic by the World health organization on March 11, 2020 [5]. Since its emergence, this pandemic has shown its capability to spread rapidly in the world causing the most dramatic global health crisis of our time resulting in devastating social, economic and political crises [6].

Globally, more than 210 countries/territories have been affected by the virus, with more than one hundred twenty six million people being infected and 2.7 million deaths reported as of March 26, 2021. Ethiopia ranks 68th regarding COVID-19 with more than 194, 000 infected and 2,741 dead (March 26, 2021) [7]. Unfortunately, Ethiopia was found to be one of five African countries with the highest case burden of COVID-19 [7]. Although, the government of Ethiopia has been striving to spread information on COVID-19 preventive measures via television, radio or social media outlets and declared a state of emergency, still the public is not consistently adhering to the precautions [8].

Currently, COVID-19 vaccine has been made available but it is highly controversial. More than
 seven billion doses have been pre-purchased by countries and organizations of the world, of

which more than half was sold-out to high income countries [9]. This figure is threatening tothe global health as may be an indication of the disparities on the health delivery globally.

Myths and conspiracy theories on vaccinations have been spreading and can easily be accepted by the developing world. This may cause people to be reluctant and maleficent towards vaccination, which has been demonstrated by a study in Nigeria by a low vaccine acceptability rate [10]. WHO defined vaccine hesitancy as it is a difficulty in accepting or an outright refusal of vaccines, despite their availability. In 2019, before the COVID-19 pandemic, the World Health Organization listed vaccine hesitancy as one of the ten global threats to public health [11].

Hence, it is crucial to understand the varying vaccine attitudes among the community to design a strategy to overcome the vaccine hesitancy. Furthermore, unraveling the specific fears and doubts of the community with regards to receiving the vaccine can help government and other concerned officials to adequately address the misconceptions and various conspiracy theories in their campaigns. Therefore, the aim of this study was to assess the level of COVID-19 vaccine acceptability among the population in Addis Ababa; the capital city of Ethiopia.

90 Methods and Materials

91 Study design and participants

A concurrent mixed-methods study (QUAN + qual) was conducted from January 20 – 31, 2021
among adult population (≥18 years) currently residing in Akaki Kality sub city of Addis Ababa,
Ethiopia. The quantitative part of the study was addressed by a cross-sectional study design and
the qualitative part of the study was addressed by a phenomenological study design. The

Page 7 of 27

BMJ Open

96 qualitative part was mainly intended to explain the reasons for COVID-19 vaccine hesitancy, as97 a supplementary of the quantitative study.

A sample size for the quantitative part of the study (n = 422) was determined by using a single population proportion formula, by taking 95% confidence interval, 5% margin of error, 50% proportion of vaccine hesitancy and adding up 10% non-response rate. For the qualitative part, aparticipants were included into the study based on the information saturation of the researchers.

Multi-stage sampling technique was employed to recruit the participants for the quantitative part of the study. There were 13 districts in the sub-city; of which three of them were selected randomly (lottery method). The total sample was allocated proportionally to the districts. Then, the households from each district were selected by employing a systematic random sampling (sampling interval = every 4th house). From the specific selected households, only one randomly selected eligible individual was interviewed. For the qualitative part of the study, purposive sampling method was used to recruit participants who have reach information.

110 Patients and public involvement

111 Neither patients nor the public was involved in the study.

112 Data collection tools and procedures

Data was collected by using a semi-structured questionnaire which was adapted from reviewed literatures [10, 12, 13]. The questionnaire has 5 components: socio-demographic, knowledge towards COVID-19, attitude towards COVID-19, practice of COVID-19 prevention measures, and COVID-19 vaccine acceptance. The questionnaire was in English and translated into Amharic for the interview. The questionnaire was administered face-to-face by the medical interns. For the qualitative part of the study, in-depth interviews were made by the investigatorsby using an in-depth interview guide.

120 Data management and analysis

Data was coded and entered into SPSS-for windows version 25 for analysis. Frequency and proportions were used to summarize categorical variables, whereas mean and standard deviation were used to summarize continuous variables.

The primary outcome variable of the study was COVID-19 vaccine hesitancy which was assessed by asking a question "Will you get vaccinated if you get COVID-19 vaccine?" then the response was dichotomized as "Yes" or "No". Knowledge of COVID-19 was assessed by 15 yes or no knowledge-based questions. Then, the knowledge score was categorized in two as below or above the mean score. The mean and below knowledge score was considered as poor knowledge while above the mean was considered as good knowledge. Attitude towards COVID-19 and its preventive measures was assessed by 11 questions which was in three Likert scale (agree, neutral, disagree) then mean score was calculated. Then, the attitude score was categorized in two as below or above the mean score. The mean and below attitude score was considered as negative attitude while above the mean was considered as positive attitude [10, 12, 13].

Multivariable binary logistic regression analysis was carried out to identify factors associated with vaccine hesitancy, as expressed by adjusted odds ratio (aOR) along with its respective 95% confidence interval (CI). Variables with <0.25 in bivariate analysis were considered for multivariable analysis. Variables having P value <0.05 were considered statistically significant. Multicollinearity was assessed by the colleniarity diagnostics (Variance Inflation Factor and the tolerance test). Goodness of the model was checked by the Hosmer Lemshow goodness of fit

Page 9 of 27

BMJ Open

141 test. The qualitative data analysis was initiated by transcription and translating of the interviews,

142 then coded and analyzed by thematic analysis. The findings of the qualitative study were used to

143 supplement the findings of quantitative data.

144 Ethical consideration

Ethical approval of this study was obtained from the Institutional Review Board (IRB) of Myungsung Medical College. The participants of the study were informed about the purpose of the study and provided their written consent. At the end of the interview, the data collectors have provided information with regard to the COVID-19 vaccine.

Results

150 Socio-demographic characteristics

A total of 409 participants completed the questionnaire, with a response rate of 96.9%. Majority
of the participants 294 (71.9%) were females and married (62.3%) (Table 1). The mean age of
the participants was 34.1 years (±12.9), ranging from 18 - 85 years.

154 Knowledge and attitude towards COVID-19 preventive measures

Almost all of the participants heard about COVID-19 from Mass-media. However, the average knowledge score was 56.7 ± 3.7 , with 46.7% (n=191) exhibited poor level of knowledge. The mean attitude score was found to be 20.3 ± 1.2 , with 51.8% of the participants have negative attitude towards COVID-19 and its preventive measures.

This results were corroborated by the findings on the qualitative part of the study where the majority of the participants stated that they were initially very concerned but now they were less so. Some participants stated that they did not believe the disease exits anymore since they have not personally encountered an infected person.

163 Participants stated the following to show how they perceive about COVID-19:

"I am not scared because I expected this to happen; we brought this on ourselves and we are paying for our sins. It has been long time coming."[*Female, 50 year old*]

''I have been through an outbreak before...I got sick and I had to be isolated from my
family but I recovered easily and I don't believe this would be any different." [Female,
47 year old]

"I was afraid that everyone in Ethiopia would die because even developed country
people could not handle it. I think the only reason we have survived is because Ethiopia
is God's country." [Female, 70 year old]

172 COVID-19 vaccine hesitancy

More than 90% of the participants heard about the COVID-19 vaccine mainly from Massmedia. However, 78 (19.1%) were not willing to get vaccinated when it becomes available (Figure 1). Out of them, 43.6% don't take the vaccine due to fear of side effects and 41.0% of them believe that the vaccine may be biological weapon (Figure 2).

In the qualitative in-depth interview, some stated they did not have enough information about the vaccine and wanted to see other people take it first. Majority of the participants feared it would not be effective or have too many side effects. A few of the participants thought that the vaccine that will be distributed in Africa would be of lower quality. Others thought it would be used as a biological weapon by the developed nations to cause infertility and control the population of poor countries. Moreover, it was also mentioned that the vaccines might be used as a weapon to insert microchips into the body as the "mark of the beast" that would cause them

BMJ Open

| 2 | |
|-----------------|--|
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| א | |
| 0 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 17 | |
| 10 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 25 | |
| 20 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | |
| 34 | |
| 25 | |
| 35 | |
| 30 | |
| 37 | |
| 38 | |
| 39 | |
| 40 | |
| 41 | |
| 42 | |
| 43 | |
| 44 | |
| 15 | |
| ر بر | |
| 40 | |
| 4/ | |
| 48 | |
| 49 | |
| 50 | |
| 51 | |
| 52 | |
| 52 | |
| 57 | |
| 54 | |
| 22 | |
| 56 | |
| 57 | |
| 58 | |
| 59 | |
| 60 | |

to forsake their faith. A few others did not think they needed the vaccine because they hadGod's protection.

186 *"I don't think the vaccine will come to this country and even if it does I don't need it;*187 *God will be my vaccine." [Female, 45 year old]*

188 Close to 20% of the participants thought that children should not get vaccinated. Some of the 189 participants did not recommend the vaccine to children even though they would take it 190 themselves. These participants further expressed in the in depth interview that they thought the 191 virus did not affect children or it would be too dangerous for them.

192 Factors associated with vaccine hesitancy

In the multi-variable analysis (Table 2), COVID-19 vaccine hesitancy was associated with sex, 193 attitude and primary source of information about the vaccine. It was found that the odds of 194 vaccine hesitancy was 1.97 times (aOR=1.97; 95% CI: 1.10 - 3.89) higher among female 195 participants as compared to male participants. The odds of vaccine hesitancy was 1.75 196 (aOR=1.75; 95% CI:1.08 - 3.02) times higher in those participants who were found to have a 197 negative attitude towards COVID-19 and its preventive measures as compared to those who had 198 a positive attitude. Similarly, the odds of vaccine hesitancy was 3.6 times (aOR=3.59; 95% CI: 199 1.75 - 7.37) higher among those participants that received their information from social media 200 (internet) as compared to those who received information only from mass-media. 201

202 **Discussion**

For the COVID-19 battle, the population adherence to preventive measures is crucial; however, it is mainly affected by their KAP toward the disease [1]. The findings of this study showed that nearly half of the study participants demonstrated inadequate knowledge of COVID-19,

indicating a great knowledge gap. This finding is higher than studies conducted in other parts of Ethiopia such as Arbaminch (23.5%) and Gedeo (39.5%), and other low income countries such as Ghana (34.9%), and Malaysia (22.7%) [14-17]. The discrepancies might be due to differences in the community awareness creation through mass media and social media. Further, in our study, more than half of the participants had negative attitude towards COVID-19 and its preventive measures, which is higher than the findings of studies conducted in Southern Ethiopia [15, 18] and lower than study done among Dessie and Kombolcha town residents in Ethiopia [19]. The discrepancy in the findings may be due to differences in the study period. The later studies were conducted earlier in the pandemic when the declaration and enforcement of state of emergency and other measures were still in place. Our findings show a significant decrease in the community's attitude towards COVID-19 and its prevention measures which can lead people to become discouraged to consistently adhere to the measures set forth by the government and the World Health Organization. These findings of the study has an implication on the public health and underscore the need for urgent concerted efforts to consistently promote the knowledge of the general public in Ethiopia towards COVID-19 preventive measures. If the current trend evidenced by this study continues in Ethiopia, COVID-19 will pose a devastating outcome on the medical, financial and social aspect of citizens besides the potential for new strains of disease developing.

As COVID-19 continues to ravage the world, vaccination offers the most reliable hope for a permanent solution to controlling the pandemic. However, a vaccine must be accepted and used by a large majority of the population to create herd immunity [20]. The findings of this study showed that about one out of five participants are not willing to receive COVID-19 vaccine when it is available, which is higher than the findings reported from developed countries such as Page 13 of 27

BMJ Open

UK (3%) [9, 21, 22]. The discrepancies might be due to insufficient knowledge about the vaccine and difference in the perception of the seriousness of the pandemic. This implies that if the doubts and fears of the majority regarding the vaccine are not addressed properly, we may not be able to attain herd immunity. Surprisingly, the finding of this study was lower than a study conducted in the US (31%) and Nigeria (80%) [13, 20]. This might be due to difference in access to wide variety of conspiracy theories and doubts via internet.

Consistent to the study conducted in China [23], vaccine hesitancy was more likely among females as compared to males in our study. This could be due to higher exposure of males for different media as compared to females in Ethiopia. In the present study, increased likelihood of vaccine hesitancy was also indicated among those with negative attitude towards COVID-19 and its preventive measures. The qualitative aspects of this study also found that those participants who would not take the vaccine stated one of their reason to be their lack of implicit trust in the government and in health professionals. Thus, this lack of confidence in the government exhibited by 41.8% of our participants may be a potential hurdle we might face during the vaccination programs in Ethiopia.

In our study, those participants who received their information from social media (internet) were more likely to have vaccine hesitancy as compared to those who got their information only from TV/radio. This finding of the study is in line with a study conducted to assess health protective behaviors and conspiracy theories during the pandemic found that there was significant association between holding a conspiracy belief and checking social media for news of COVID-19 [24]. As a result, this finding is justified by our findings on both the quantitative and qualitative aspects of our study which found that the majority of the reasons given for hesitancy towards the vaccine were the belief in the conspiracy theories. Thus, the spared of

these conspiracy theories is a potential issue that can cause problems when vaccine distribution starts in Ethiopia. Particularly, if these conspiracy theories start getting a wider audience thus there may be a need to act in haste and find a solution before this issue worsens.

This study is the first community based study to assess the Ethiopian community's perception towards COVID-19 vaccine and its level of acceptance. We employed a mixed methods design which enables us to make the deep understanding of the issue. However, the study might be limited due to the recall bias and social desirability bias during the data collection. In addition to this, our sample over-represents female population because the majority of the study participants that were found at home during data collection time were housewives. Therefore, generalization of the study results needs to be cautious.

Conclusions

A considerable proportion of the people have concerns of the COVID-19 vaccine and unwilling to accept once it is available. Several conspiracy theories were put forth to justify their stance and this was mainly due to the misconceptions distributed from the use of social media as primary source of information about the vaccine. These findings of the study underscore the need to use social-media as a way to disseminate reliable information with regard to COVID-19 vaccination and the preventive measures, rather than only focusing on the mass-media messages. Overall, providing the community with health education and consistent government efforts in uphold the prevention measures are of paramount importance to tackle this pandemic.

271 List of Abbreviations

272 aOR: Adjusted Odds Ratio

59

| 1 2 | | |
|----------------------|-----|---|
| 2 3 4 | 273 | CI: Confidence Interval |
| 5 6 7 | 274 | COR: Crude Odds Ratio |
| 8 9 10 | 275 | SARS: Severe Acute Respiratory Syndrome |
| 11 12 13 | 276 | UK: United Kingdom |
| 14 15 16 17 | 277 | US: United States |
| 18 19 20 | 278 | Declarations |
| 21 22 23 | 279 | Consent for publication |
| 24 25 26 | 280 | Not applicable |
| 20 27 28 | 281 | Availability of data and material |
| 29 30 31 | 282 | Data are available upon reasonable request from the corresponding author. |
| 32 33 34 | 283 | Competing interests |
| 35 36 | 284 | The authors declare that they have no competing interests. |
| 37 38 39 | 285 | Authors Contributions |
| 40 41 | 286 | N.D., A.T., B.T., and D.A. conceptualized the study, designed the methodology, analyzed the |
| 42 43 44 | 287 | data, interpreted the results and drafted the initial manuscript and approved the final manuscript. |
| 45 46 | 288 | H.A., N.T., S.G., T.B., and Y.L. conceptualized the study, visualized the data, involved in data |
| 47 48 40 | 289 | analysis and interpretation and approved the final manuscript. All authors have read and |
| 50 51 | 290 | approved the manuscript. |
| 52 53 | | |
| 54 55 | | |
| 56 | | |

Acknowledgements

The authors would like to thank Myungsung Medical College for providing fund to conduct this study. The authors are grateful to the study participants for their contributions.

Ethics approval statement

Ethical approval of this study was obtained from the Institutional Review Board (IRB) of Myungsung Medical College. The participants of the study were informed about the purpose of the study and provided their written consent. At the end of the interview, the data collectors have provided information with regard to the COVID-19 vaccine.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| 1 2 | | | | | | |
|--|-----|---|--|--|--|--|
| 2 3 4 | 300 | Reference | | | | |
| 5 6 7 | 301 | 1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 82. | | | | |
| , 8 9 | 302 | 2020. | | | | |
| 10 11 | 303 | 2. Imai N, Dorigatti I, Cori A, Donnelly C, Riley S, Ferguson N. Report 2: Estimating the | | | | |
| 12 13 | 304 | potential total number of novel Coronavirus cases in Wuhan City, China. 2020. | | | | |
| 14 15 16 | 305 | 3. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. | | | | |
| 17 18 | 306 | Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New England | | | | |
| 19 20 | 307 | journal of medicine. 2020;382(10):970-1. | | | | |
| 21 22 23 | 308 | 4. Ranney ML, Griffeth V, Jha AK. Critical supply shortages—the need for ventilators and | | | | |
| 24 25 | 309 | personal protective equipment during the Covid-19 pandemic. New England Journal of | | | | |
| 26 27 | 310 | Medicine. 2020;382(18):e41. | | | | |
| 28 29 30 31 32 33 34 35 36 | 311 | 5. Assessment RR. Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK- | | | | |
| | 312 | ninth update. European Centre for Disease Prevention and Control: Stockholm. 2020. | | | | |
| | 313 | 6. COVID C. Global Cases by the Center for Systems Science and Engineering (CSSE) at | | | | |
| | 314 | Johns Hopkins University (JHU). JHU COVID-19 Resource Center. Johns Hopkins | | | | |
| 37 38 39 | 315 | Coronavirus Resource Center. 2020. | | | | |
| 40 41 | 316 | 7. Worldometer. Coronavirus Update (Live): Cases and Deaths from COVID-19 Virus | | | | |
| 42 43 | 317 | Pandemic2021[cited2021Feb24].Availablefrom: | | | | |
| 44 45 | 318 | https://www.worldometers.info/coronavirus/. | | | | |
| 40 47 48 | 319 | 8. Zikargae MH. COVID-19 in Ethiopia: Assessment of How the Ethiopian Government | | | | |
| 49 50 | 320 | has Executed Administrative Actions and Managed Risk Communications and Community | | | | |
| 51 52 | 321 | Engagement. Risk management and healthcare policy. 2020;13:2803. | | | | |
| 53 54 55 | | | | | | |
| 56 57 | | | | | | |
| 58 59 | | 16 | | | | |
| 60 | | i or been review only - urth// pulloben/pull/sire/aport/dridelines/sirtini | | | | |

| 2 | |
|------------------------|--|
| 2 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 10 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| ע∠ 1 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 21 | |
| 21 | |
| 32 | |
| 33 | |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | |
| 40 | |
| - 1 0 /1 | |
| 41 | |
| 42 | |
| 43 | |
| 44 | |
| 45 | |
| 46 | |
| 47 | |
| 48 | |
| 49 | |
| 50 | |
| 50 | |
| 51 | |
| 52 | |
| 53 | |
| 54 | |
| 55 | |
| 56 | |
| 57 | |
| 58 | |
| 59 | |
| 50 | |

1 2

Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views
on the acceptability of a future COVID-19 vaccine: A multi-methods study in England.
Vaccine. 2020;38(49):7789-98.

Reuben RC, Danladi MM, Saleh DA, Ejembi PE. Knowledge, attitudes and practices
towards COVID-19: an epidemiological survey in North-Central Nigeria. Journal of community
health. 2020:1-14.

328 11. Graffigna G, Palamenghi L, Boccia S, Barello S. Relationship between citizens' health
329 engagement and intention to take the covid-19 vaccine in italy: A mediation analysis. Vaccines.
330 2020;8(4):576.

Ma L, Liu H, Tao Z, Jiang N, Wang S, Jiang X. Knowledge, Beliefs/Attitudes, and
practices of rural residents in the prevention and control of COVID-19: an online questionnaire
survey. The American journal of tropical medicine and hygiene. 2020;103(6):2357-67.

13. Enitan S, Oyekale A, Akele R, Olawuyi K, Olabisi E, Nwankiti A. Assessment of
Knowledge, Perception and Readiness of Nigerians to participate in the COVID-19 Vaccine
Trial. International Journal of Vaccines and Immunization. 2020;4:1-13.

337 14. Aweke Z, Jemal B, Mola S, Hussen R. Knowledge of COVID-19 and its prevention
338 among residents of the Gedeo zone, South Ethiopia. Sources of information as a factor. Current
339 Medical Research and Opinion. 2020;36(12):1955-60.

340 15. Nigussie TF, Azmach NN. Knowledge, attitude and practice towards covid-19 among
 341 Arba Minch town, southern Ethiopia. GSJ. 2020;8(6).

342 16. Nkansah C, Serwaa D, Adarkwah LA, Osei-Boakye F, Mensah K, Tetteh P, et al. Novel
343 coronavirus disease 2019: knowledge, practice and preparedness: a survey of healthcare
344 workers in the Offinso-North District, Ghana. The Pan African Medical Journal. 2020;35(79).

BMJ Open

| 2 | |
|----------|--|
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| / 0 | |
| 0 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 32 | |
| 27 | |
| 25 | |
| 26 | |
| 30 27 | |
| 3/ | |
| 38 | |
| 39 | |
| 40 | |
| 41 | |
| 42 | |
| 43 | |
| 44 | |
| 45 | |
| 46 | |
| 47 | |
| 48 | |
| 49 | |
| 50 | |
| 51 | |
| 52 | |
| 53 | |
| 54 | |
| 55 | |
| 56 | |
| 57 | |
| 58 | |
| 59 | |
| 60 | |
| 00 | |

345 17. Mohamad EM, Azlan AA, Hamzah MR, Tham JS, Ayub SH. Public knowledge,
346 attitudes and practices towards COVID-19: A cross-sectional study in Malaysia. medRxiv.
347 2020.

348 18. Mola S, Aweke Z, Jemal B, Hussein R, Hailu S, Neme D, et al. Magnitude and
349 associated factors for attitude and practice of Southern Ethiopian residents toward COVID-19
350 and its preventions: A community based cross sectional study. 2020.

- 351 19. Kassa AM, Mekonen AM, Yesuf KA, Tadesse AW, Bogale GG. Knowledge level and
 352 factors influencing prevention of COVID-19 pandemic among residents of Dessie and
 353 Kombolcha City administrations, North-East Ethiopia: a population-based cross-sectional study.
 354 BMJ open. 2020;10(11):e044202.
- ⁶ 355 20. Pogue K, Jensen JL, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, et al. Influences
 ⁸ 356 on attitudes regarding potential COVID-19 vaccination in the United States. Vaccines.
 ⁹ 357 2020;8(4):582.
- 358 21. Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Acceptance of
 359 a COVID-19 vaccine in southeast Asia: A cross-sectional study in Indonesia. Frontiers in public
 360 health. 2020;8.
- 361 22. Salali GD, Uysal MS. COVID-19 vaccine hesitancy is associated with beliefs on the 362 origin of the novel coronavirus in the UK and Turkey. Psychological medicine. 2020:1-3.
- 363 23. Wang J, Jing R, Lai X, Zhang H, Lyu Y, Knoll MD, et al. Acceptance of COVID-19
 Vaccination during the COVID-19 Pandemic in China. Vaccines. 2020;8(3):482.
 - 365 24. Allington D, Duffy B, Wessely S, Dhavan N, Rubin J. Health-protective behaviour,
 366 social media usage and conspiracy belief during the COVID-19 public health emergency.
 367 Psychological medicine. 2020:1-7.

| 1 | | |
|----------|-----|---|
| 2 | | |
| 3 4 | 368 | |
| 5 | | |
| 6 | 369 | Figure captions |
| 7 | 000 | |
| 8 | | |
| 9 10 | 370 | Figure 1: COVID-19 vaccine acceptance |
| 11 | 371 | Figure 2: Reasons of participant for refusing COVID-19 vaccination |
| 12 | | |
| 13 | 372 | |
| 14 15 | | |
| 16 | | |
| 17 | | |
| 18 | | |
| 19 20 | | |
| 20 21 | | |
| 22 | | |
| 23 | | |
| 24 | | |
| 25 | | |
| 20 27 | | |
| 28 | | |
| 29 | | |
| 30 | | |
| 31 | | |
| 33 | | |
| 34 | | |
| 35 | | |
| 36 37 | | |
| 38 | | |
| 39 | | |
| 40 | | |
| 41 42 | | |
| 42 | | |
| 44 | | |
| 45 | | |
| 46 | | |
| 47 48 | | |
| 49 | | |
| 50 | | |
| 51 | | |
| 52 52 | | |
| 55 54 | | |
| 55 | | |
| 56 | | |
| 57 | | |
| 58 50 | | |
| 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |

| | | Frequency (N) | Percent (% |
|----------------|----------------------|---------------|------------|
| Sex | Male | 115 | 28.1% |
| | Female | 294 | 71.9% |
| Age | 18-29 | 174 | 42.5% |
| | 30-40 | 147 | 35.9% |
| | 41-50 | 40 | 9.8% |
| | >50 | 48 | 11.7% |
| Marital status | Not married | 123 | 30.1% |
| | Married | 255 | 62.3% |
| | Widowed | 20 | 4.9% |
| | Divorced | 11 | 2.7% |
| Religion | Christian | 349 | 85.3% |
| | Muslim | 60 | 14.7% |
| Educational | No formal education | 39 | 9.5% |
| status | Primary school | 105 | 25.7% |
| | Secondary and above | 265 | 64.8% |
| Occupation | Unemployed/housewife | 190 | 46.5% |
| | Employed | 219 | 53.5% |
| Monthly | ≤3200 ETB (≤100 USD) | 175 | 42.8% |
| income* | >3200 ETB (>100 USD) | 228 | 57.2% |

373 Table 1: Socio-demographic characteristics of the study participants



| Variables | Vaccine hesitancy | | cOR (95% CI) | aOR(95% CI) | Р |
|--------------------|-------------------|-------------|------------------|------------------|-------|
| | Yes (%) | No (%) | | | value |
| Sex | | | | | |
| Male | 17 (21.8%) | 98 (29.6%) | 1.00 | 1.00 | |
| Female | 61 (78.2%) | 233 (70.4%) | 1.49 (0.83-2.69) | 1.97 (1.10-3.89) | 0.03 |
| Age | | | | | |
| 18-29 | 34 (43.6%) | 140 (42.3%) | 1.00 | 1.00 | |
| 30-40 | 24 (30.8%) | 122 (36.9%) | 0.81 (0.46-1.44) | 1.03 (0.55-1.92) | 0.934 |
| 41-50 | 12 (15.4%) | 29 (8.8%) | 1.77 (0.82-3.82) | 2.22 (0.94-5.21) | 0.067 |
| >50 | 8 (10.2%) | 40 (12.0%) | 0.82 (0.35-1.92) | 1.08 (0.39-2.97) | 0.892 |
| Religion | | 7 | • | | |
| Christian | 8 (10.3%) | 52 (15.7%) | 1.00 | 1.00 | |
| Muslim | 70 (89.7%) | 278 (84.3%) | 1.64 (0.74-3.60) | 1.23 (0.54-2.83) | 0.621 |
| Educational status | | | | | |
| No formal | 9 (11.5%) | 30 (9.1%) | 1.11 (0.50-2.48) | 1.11 (0.39-3.16) | 0.840 |
| education | | | | | |
| Primary education | 13 (16.7%) | 93 (28.1%) | 0.53 (0.27-1.01) | 0.81 (0.40-1.63) | 0.560 |
| Secondary and | 56 71.8%) | 208 (62.8%) | 1.00 | 1.00 | |
| above | | | | | |
| Attitude | | | | | |
| Positive attitude | 28 (35.9%) | 169 (51.1%) | 1.00 | 1.00 | |

| 376 | Table 2: Factors | associated with | COVID-19 | vaccine | hesitancy in | Addis Ababa, | Ethiopia, | 2021 |
|-----|------------------|-----------------|----------|---------|--------------|--------------|-----------|------|
|-----|------------------|-----------------|----------|---------|--------------|--------------|-----------|------|

| Negative attitude | 50 (64 1%) | 162 (48 9%) | 1 87 (1 12 - 3 12) | 1.75(1.08-3.02) |
|-------------------|-------------|--------------|--------------------|------------------|
| Regative attitude | 50 (04.170) | 102 (40.970) | 1.07 (1.12-5.12) | 1.75 (1.06-5.02) |
| Primary source of | information | | | |
| TV/Radio | 38 (48.7%) | 255 (77.0%) | 1.00 | 1.00 |
| Social media | 40 (51.3%) | 76 (23.0%) | 3.53 (1.67-6.98) | 3.59 (1.75-7.37) |
| (internet) | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

80.4%





STROBE Statement-checklist of items that should be included in reports of observational studies

| | Item No. | Recommendation | Page No. |
|---------------------|-------------|---|-------------------------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | Title page, Page No.1 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Abstract, Page No.2 |
| Introduction | | | |
| Background/rational | e 2 | Explain the scientific background and rationale for the investigation being reported | Introduction, Page No. 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Introduction, Page No. 5 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | Methods, Page No. 6 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow- | Methods, Page No. 6 |
| | | up, and data collection | |
| Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. | Methods, Page No. 6 |
| | | Describe methods of follow-up | |
| | | <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and | |
| | | control selection. Give the rationale for the choice of cases and controls | |
| | | Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of | |
| | | participants | |
| | | (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed | N/A |
| | | Case-control study—For matched studies, give matching criteria and the number of controls per case | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give | Methods, Data management and |
| | | diagnostic criteria, if applicable | analysis, Page No. 7 and 8 |
| Data sources/ | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). | Methods, Data tools and procedures, |
| measurement | | Describe comparability of assessment methods if there is more than one group | Page No. 7 |
| Bias | 9 | Describe any efforts to address potential sources of bias | Methods, Data tools and procedures, |
| | | | Page No. 7; Data management and |
| | | | analysis, Page No. 7 and 8 |
| Study size | 10 | Explain how the study size was arrived at | Methods, Page No. 5 |
| Quantitative | 11 E | xplain how quantitative variables were handled in the analyses. If applicable, describe which groupings | Methods, Data management and |
| variables | W | vere chosen and why | analysis, Page No. 7 and 8 |

| Statistical | 12 | (a) Describe all statistical methods, including those used to control for confounding | Methods, Data management and |
|------------------|-----|--|------------------------------|
| methods | | | analysis, Page No. 7 and 8 |
| | | (b) Describe any methods used to examine subgroups and interactions | Methods, Data management and |
| | | | analysis, Page No. 7 and 8 |
| | | (c) Explain how missing data were addressed | N/A |
| | | (d) Cohort study—If applicable, explain how loss to follow-up was addressed | N/A |
| | | Case-control study-If applicable, explain how matching of cases and controls was addressed | |
| | | Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy | |
| | | (<u>e</u>) Describe any sensitivity analyses | N/A |
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for | N/A |
| | | eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | |
| | | (b) Give reasons for non-participation at each stage | N/A |
| | | (c) Consider use of a flow diagram | N/A |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures | Results, Page No. 9 and 10 |
| | | and potential confounders | |
| | | (b) Indicate number of participants with missing data for each variable of interest | N/A |
| | | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) | N/A |
| Outcome data | 15* | Cohort study—Report numbers of outcome events or summary measures over time | N/A |
| | | Case-control study-Report numbers in each exposure category, or summary measures of exposure | |
| | | Cross-sectional study—Report numbers of outcome events or summary measures | Results, Page No. 9 and 10 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% | Results, Page No. 9 and 10 |
| | | confidence interval). Make clear which confounders were adjusted for and why they were included | |
| | | (b) Report category boundaries when continuous variables were categorized | N/A |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A |

Continued on next page

| Other analyses | 17 | Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses | N/A | |
|------------------|----|--|--------------------------------|--|
| Discussion | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Discussion, Page No. 10 | |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discussion, Page No. 12 | |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Conclusions, Page No. 12 | |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Discussion, Page No. 12 | |
| Other informati | on | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original | Source of funding, Page No. 14 | |
| | | study on which the present article is based | | |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

 Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: A mixed-methods study

| Journal: | BMJ Open |
|--------------------------------------|---|
| Manuscript ID | bmjopen-2021-052432.R1 |
| Article Type: | Original research |
| Date Submitted by the Author: | 07-Mar-2022 |
| Complete List of Authors: | Dereje, Nebiyu; MyungSung Medical College, Department of Public Health Tesfaye, Abigel; MyungSung Medical College, Department of Medicine Tamene, Beamlak; MyungSung Medical College, Department of Medicine Alemeshet, Dina; MyungSung Medical College, Department of Medicine Abe, Haymanot; MyungSung Medical College, Department of Medicine Tesfa, Nathnael; MyungSung Medical College, Department of Medicine Gedion, Saron; MyungSung Medical College, Department of Medicine Biruk, Tigist; MyungSung Medical College, Department of Medicine Lakew, Yabets; MyungSung Medical College, Department of Medicine |
| Primary Subject Heading : | Public health |
| Secondary Subject Heading: | Epidemiology |
| Keywords: | COVID-19, Public health < INFECTIOUS DISEASES, EPIDEMIOLOGY |
| | |





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| 2 | |
|----------|--|
| 3 | |
| Δ | |
| 5 | |
| ر ح | |
| 0 | |
| / | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 10 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 2⊿ | |
| 24 25 | |
| 20 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | |
| 34 | |
| 35 | |
| 36 | |
| 20 | |
| 3/ | |
| 38 | |
| 39 | |
| 40 | |
| 41 | |
| 42 | |
| 43 | |
| 44 | |
| 45 | |
| 46 | |
| 17 | |
| 47 | |
| 40 | |
| 49 | |
| 50 | |
| 51 | |
| 52 | |
| 53 | |
| 54 | |
| 55 | |
| 56 | |
| 57 | |
| 57 | |
| 20 | |
| 59 | |
| 60 | |

11

1

COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: A mixed-methods study 1

- Nebiyu Dereje1*, Abigel Tesfaye2, Beamlak Tamene2, Dina Alemeshet2, Haymanot Abe2, 2
- Nathnael Tesfa², Saron Gedion², Tigist Biruk², Yabets Lakew² 3
- ¹Department of Public Health, Myungsung Medical College, Addis Ababa, Ethiopia 4
- ²Department of Medicine, Myungsung Medical College, Addis Ababa, Ethiopia 5
- *Corresponding author contact information 6
- Nebiyu Dereje 7
- Email: neba.jahovy@gmail.com 8
- P.O.Box 14972 9
- Addis Ababa, Ethiopia 10

12 Abstract

Objective: Data on COVID-19 vaccine hesitancy is limited in Ethiopia and other parts of
Africa. Therefore, the aim of this study was to determine the level of COVID-19 vaccine
hesitancy and its associated factors in Addis Ababa, Ethiopia.

Design: A community-based concurrent mixed-methods study

17 Setting: In a community setting

Participants: Adult residents (n = 422) of Akaki Kality sub-city who were recruited by a multistage sampling technique and 24 adults who were selected purposively were included for the
quantitative and qualitative part of the study respectively.

Outcome Measures: Data were collected by face-to-face interview using a semi-structured questionnaire. Factors associated with COVID-19 vaccine hesitancy were identified by multivariable binary logistic regression model.

Results: One out five (19.1%, 95% CI: 15.3% - 24.6%) participants were not willing to get vaccinated. In the multivariable analysis, vaccine hesitancy was significantly associated with being female (aOR=1.97; 95% CI: 1.10 - 3.89), having negative attitude towards COVID-19 and its preventive measures (aOR=1.75; 95% CI: 1.08 - 3.02), and primary information source being social media (internet) (aOR=3.59; 95% CI: 1.75 - 7.37). Study participants have predominantly stated that they did not have enough information about the vaccine, feared it would not be effective or have too many side effects, and reflected their uncertainty towards the quality of the vaccine.

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |
| 26 |
| 27 |
| 28 |
| 29 |
| 30 |
| 31 |
| 32 |
| 33 |
| 34 |
| 35 |
| 36 |
| 37 |
| 38 |
| 39 |
| 40 |
| 41 |
| 42 |
| 43 |
| 44 |
| 45 |
| 46 |
| 47 |
| 48 |
| 49 |
| 50 |
| 51 |
| 52 |
| 53 |
| 54 |
| 55 |
| 56 |
| 57 |
| 58 |
| 59 |

60

1 2

Conclusions: A considerable proportion of the people in Addis Ababa have concerns on 32 COVID-19 vaccines and unwilling to accept them. This was due to the misconceptions, 33 negative attitudes, and use of social media as their primary source of information. Providing the 34 community with health education and consistent efforts to enhance the prevention measures are 35 important, particularly using different medias including social media. 36 **Key Words**: COVID-19, knowledge, attitude, Vaccine, Hesitancy 37 **Article Summary** 38 Strengths and limitations of this study 39 We employed a community-based study which could reflect the prevailing COVID 19 40 vaccine hesitancy in the general population. 41 A mixed-methods approach allows for triangulation of findings from different 42 43 perspectives. Factors associated with the outcome variable (vaccine hesitancy) were adjusted for the 44 known explanatory variables. 45 The study might be limited due to the social desirability bias during the data collection. 46 **Funding statement** 47 This study was funded by Myungsung Medical College. However, the funder had no role in the 48 49 design, conduct, analysis and interpretation of this study. 50 **Conflict of interest** The authors declare that they have no conflict of interests. 51 Word count =2868 52

| 1 | | |
|-----------|----|---|
| 2 | | |
| 3 | 53 | |
| 4 | | |
| 5 | | |
| 6 | | |
| / | | |
| 8 | | |
| 9 10 | | |
| 10 | | |
| 12 | | |
| 13 | | |
| 14 | | |
| 15 | | |
| 16 | | |
| 17 | | |
| 18 | | |
| 19 20 | | |
| 20 | | |
| ∠ I วว | | |
| ∠∠ 23 | | |
| 24 | | |
| 25 | | |
| 26 | | |
| 27 | | |
| 28 | | |
| 29 | | |
| 30 | | |
| 31 | | |
| 32 33 | | |
| 34 | | |
| 35 | | |
| 36 | | |
| 37 | | |
| 38 | | |
| 39 | | |
| 40 | | |
| 41 | | |
| 42 /2 | | |
| 43 | | |
| 45 | | |
| 46 | | |
| 47 | | |
| 48 | | |
| 49 | | |
| 50 | | |
| 51 | | |
| 52 | | |
| 53 | | |
| 54 55 | | |
| 55 56 | | |
| 50 | | |
| 58 | | |
| 59 | | |
| 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |

54 Introduction

Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) also known as Novel coronavirus (nCov) [1]. Since its emergence, this pandemic has shown its capability to spread rapidly in the world causing the most dramatic global health crisis of our time resulting in devastating social, economic and political crises [2]. Therefore, on top of other preventive measures, it is crucial to receive COVID vaccines to halt the spread of COVID-19 [3].

Globally, more than 210 countries/territories have been affected by the virus, and Ethiopia is one of the five African countries with the highest case burden of COVID-19 [4]. Although, the government of Ethiopia has been striving to spread information on COVID-19 preventive measures, still the public is not consistently adhering to the precautions [5]. On the other hand, although the COVID-19 vaccines have been made available, it is highly controversial, as they are highly affected by disparities of access and distributions across the countries, where large proportions of the vaccines have been already sold-out to high-income countries [6].

Moreover, myths and conspiracy theories on vaccinations have been spreading and can easily be
accepted by the developing world. This may cause people to be reluctant towards vaccination,
which has been demonstrated by a study in Nigeria by a low vaccine acceptability rate [7].
Furthermore, the World Health Organization listed vaccine hesitancy as one of the ten global
threats to public health [8].

Some recent studies have also reported the magnitude of vaccine hesitancy varying from 76.4% to 3.0%, indicating variabilities across different countries [9 - 11]. This variability could be partly due to varying perceptions and attitudes towards the efficacy, quality and safety of the

BMJ Open

COVID vaccines. Vaccine hesitancy could also be affected by the socio-demographic, psychological and cultural factors of the population. Therefore, it is imperative to understand the varying vaccine attitudes among the community to design strategies to overcome the vaccine hesitancy. Furthermore, unraveling the specific fears and doubts of the community with regards to receiving the vaccine can help government and other concerned officials to adequately address the misconceptions and various conspiracy theories in their campaigns.

82 Methods and Materials

83 Study design and participants

A concurrent mixed-methods study (QUAN + qual) was conducted from January 20 - 31, 2021 among adult population (≥ 18 years) currently residing in Akaki Kality sub city of Addis Ababa, Ethiopia. The quantitative part of the study was addressed by a cross-sectional study design and the qualitative part of the study was addressed by a phenomenological study design. The qualitative part was mainly intended to explain the reasons for COVID-19 vaccine hesitancy, as a supplementary of the quantitative part.

A sample size for the quantitative part of the study (n = 422) was determined by using a single population proportion formula, by taking 95% confidence interval, 5% margin of error, 50% proportion of vaccine hesitancy and adding up 10% non-response rate. For the qualitative part, 24 participants were included into the study based on the information saturation of the researchers.

Two-stage sampling technique was employed to recruit the participants for the quantitative part of the study. There were 13 districts in the sub-city; of which three of them were selected randomly (lottery method). The total sample was allocated proportionally to the districts. Then,

> 98 the households from each district were selected by employing a systematic random sampling 99 (sampling interval = every 4th house). From the specific selected households, only one randomly 100 selected eligible individual was interviewed. For the qualitative part of the study, purposive 101 sampling method was used to recruit participants who have reach information.

102 Patients and public involvement

103 Neither patients nor the public was involved in the study.

104 Data collection tools and procedures

Data was collected by using a semi-structured questionnaire which was adapted from reviewed literatures [7, 12, 13]. The contents of the questionnaire were validated by senior experts in the field. The questionnaire has 4 components: socio-demographic, knowledge towards COVID-19, attitude towards COVID-19, and COVID-19 vaccine acceptance. The questionnaire was first prepared in English and translated into Amharic (local language) for the sake of interview. The questionnaire was administered face-to-face by trained medical interns. For the qualitative part of the study, in-depth interviews were made by the investigators by using an in-depth interview guide (supplementary file 1).

113 Data management and analysis

114 Data was checked for completeness and consistency, coded and entered into SPSS-for windows 115 version 25 for analysis. Frequency and proportions were used to summarize categorical 116 variables, whereas mean and standard deviation were used to summarize continuous variables.

117 The primary outcome variable of the study was COVID-19 vaccine hesitancy which was 118 assessed by asking a question "Will you get vaccinated if you get COVID-19 vaccine?" then the 119 response was dichotomized as "Yes" or "No". Knowledge of COVID-19 was assessed by 15

Page 9 of 34

BMJ Open

yes or no knowledge-based questions. Then, the knowledge score was categorized in two as below or above the mean score. The mean and below knowledge score was considered as poor knowledge while above the mean was considered as good knowledge. Attitude towards COVID-19 and its preventive measures was assessed by 11 questions which was in three Likert scale (agree, neutral, disagree) then mean score was calculated. Then, the attitude score was categorized in two as below or above the mean score. The mean and below attitude score was considered as negative attitude while above the mean was considered as positive attitude [7, 12, 13].

Multivariable binary logistic regression analysis was carried out to identify factors associated with vaccine hesitancy, as expressed by adjusted odds ratio (aOR) along with its respective 95% confidence interval (CI). Variables with <0.25 in bivariate analysis were considered for multivariable analysis. The explanatory variables entered into the multivariable model include sex, age, educational status, religion, attitude and primary source of information. Variables having *P* value <0.05 were considered statistically significant. Multicollinearity was assessed by the colleniarity diagnostics (Variance Inflation Factor (2.30) and the tolerance test (0.43)). Goodness of the model was checked by the Hosmer Lemshow goodness of fit test, and it was not significant (P value = 0.81). The qualitative data analysis was initiated by transcription and translating of the interviews, then coded and analyzed by thematic analysis. The findings of the qualitative study were used to supplement the findings of quantitative data.

139 Ethical consideration

Ethical approval of this study was obtained from the Institutional Review Board (IRB) of
Myungsung Medical College (MMC/IRB/067/21). The participants of the study were informed

| 3 4 | 142 | about t |
|----------------|-----|----------|
| 5 6 7 | 143 | the data |
| 8 9 10 | 144 | Resul |
| 11 12 13 | 145 | Socio-o |
| 14 15 | 146 | A total |
| 16 17 18 | 147 | of the p |
| 19 20 | 148 | age of |
| 21 22 23 | 149 | Knowl |
| 24 25 | 150 | Almost |
| 26 27 28 | 151 | SD) kn |
| 28 29 30 | 152 | The me |
| 31 32 | 153 | negativ |
| 33 34 35 | 154 | These |
| 36 37 | 155 | particip |
| 38 39 | 156 | 19. Pai |
| 40 41 42 | 157 | disease |
| 43 44 | 158 | believi |
| 45 46 47 | 159 | predom |
| 48 49 50 | 160 | Particip |
| 51 52 | 161 | |
| 53 54 55 | 162 | |
| 56 57 | | |
| 58 50 | | |
| 60 | | |

he purpose of the study and provided their written consent. At the end of the interview,

a collectors have provided information regarding the COVID-19 vaccine.

ts

1 2

demographic characteristics

of 409 participants completed the questionnaire, with a response rate of 96.9%. Majority participants 294 (71.9%) were females and married (62.3%) (Table 1). The mean $(\pm SD)$ the participants was 34.1 years (± 12.9) , ranging from 18 - 85 years.

edge and attitude towards COVID-19 preventive measures

t all the participants heard about COVID-19 from Mass-media. However, the average (\pm nowledge score was 56.7 ± 3.7 , with 46.7% (n=191) exhibited poor level of knowledge. ean (\pm SD) attitude score was found to be 20.3 \pm 1.2, with 51.8% of the participants had re attitude towards COVID-19 and its preventive measures.

results were corroborated by the findings of the qualitative part of the study where bants stated that they were initially very concerned about getting infected with COVIDradoxically, participants also stated that they did not believe on the existence of the since they have not personally encountered an infected person. On the other hand, ng COVID-19 disease as if it was emanated because of the punishment of God was ninantly explained by the participants.

pants stated the following to show how they perceived about COVID-19:

"I am not scared because I expected this to happen; we brought this on ourselves, and we are paying for our sins. It has been long time coming." [Female, 50-year-old]

BMJ Open

| 1 2 | | |
|----------------------|-----|---|
| 2 3 4 | 163 | "I have been through an outbreak beforeI got sick, and I had to be isolated from my |
| 5 6 | 164 | family, but I recovered easily, and I don't believe this would be any different." [Female, |
| 7 8 9 | 165 | 47-year-old] |
| 10 11 | 166 | "I was afraid that everyone in Ethiopia would die because even developed country |
| 12 13 | 167 | people could not handle it. I think the only reason we have survived is because Ethiopia |
| 14 15 16 | 168 | is God's country." [Female, 70-year-old] |
| 17 18 19 | 169 | COVID-19 vaccine hesitancy and its associated factors |
| 20 21 | 170 | More than 90% of the participants heard about the COVID-19 vaccine mainly from Mass- |
| 22 23 24 | 171 | media. However, 78 (19.1%, 95% CI: 15.3% - 24.6%) were not willing to get vaccinated. Out |
| 25 26 | 172 | of them, 43.6% don't take the vaccine due to fear of side effects and 41.0% of them believe that |
| 27 28 29 | 173 | the vaccine may be biological weapon (Figure 1). |
| 30 31 | 174 | In the qualitative in-depth interview, participants stated that they did not have enough |
| 32 33 34 | 175 | information about the vaccine and wanted to see other people take it first. For instance, a young |
| 35 36 | 176 | man said that: |
| 37 38 39 | 177 | "frankly speaking, I do not have adequate information about the COVID vaccine, |
| 40 41 42 | 178 | and for sure I will not receive it until I see others take it first" [Male, 32-year-old] |
| 42 43 44 45 | 179 | Participants also described their concerns over the effectiveness and quality of the vaccines. |
| 46 47 | 180 | "I fear that the vaccines might not be effective or of a lower quality, particularly |
| 48 49 | 181 | those vaccines distributed to Africa. They may also have serious side effects, as they did |
| 50 51 52 | 182 | not take longer time in laboratories or in trials before they are released for use." [Male, |
| 52 53 54 | 183 | 45-year-old] |
| 55 56 57 | | |
| 57 58 59 | | 10 |

| 2 3 4 | 184 | |
|--|-----|---|
| 5 6 7 | 185 | Other predominant thought expressed by the participants was the vaccines would be used by the |
| 8 9 | 186 | developed nations to cause infertility and control the population size of poor countries. For |
| 10 11 12 | 187 | example, participants stated that: |
| 13 14 15 | 188 | "I saw some videos circulating on social media stating that the vaccines are made |
| 16 17 | 189 | to reduce the population size of the poor countries" [Female, 35-year-old] |
| 19 20 | 190 | Moreover, it was also mentioned that the vaccines might be used as a weapon to insert |
| 21 22 | 191 | microchips into the body as the "mark of the beast" that would cause them to forsake their faith. |
| 23 24 25 | 192 | "it seems the end of the world is nearas it is stated in the Bible, during the end |
| 26 27 | 193 | times the mark of the beast will be labelled on the peopleI fear these vaccines may be |
| 28 29 30 | 194 | associated to this" [Male, 40-year-old] |
| 31 32 33 | 195 | A few others did not think they needed the vaccine because they had God's protection. |
| 34 35 26 | 196 | "I don't think the vaccine will come to this country and even if it does, I don't need |
| 30 37 38 | 197 | it; God will be my vaccine." [Female, 45-year-old] |
| 39 40 41 | 198 | In the multi-variable analysis (Table 2), COVID-19 vaccine hesitancy was associated with |
| 42 43 | 199 | being female, having negative attitude towards the vaccine and primary source of information |
| 44 45 46 | 200 | about the vaccine being social media. The odds of vaccine hesitancy was 2 times (aOR=1.97; |
| 47 48 | 201 | 95% CI: 1.10 - 3.89) higher among female participants as compared to male participants,1.8 |
| 49 50 | 202 | times (aOR=1.75; 95% CI:1.08 - 3.02) higher among participants who have negative attitudes |
| 51 52 53 54 55 56 57 | 203 | towards COVID-19 as compared to those who had positive attitudes, and 4 times (aOR=3.59; |
| 57 58 | | 11 |

BMJ Open

95% CI: 1.75 - 7.37) higher among those participants who got information from social media as a primary source as compared to those who received information only from mass-media.

Discussion

For the COVID-19 battle, the population adherence to preventive measures and receiving COVID vaccines is crucial; however, it is mainly affected by their knowledge and attitude towards the disease and vaccination [1]. The findings of this study showed that nearly half of the study participants demonstrated inadequate knowledge of COVID-19, indicating a great knowledge gap. This finding is higher than studies conducted in other parts of Ethiopia such as Arbaminch (23.5%) and Gedeo (39.5%), and other countries such as Ghana (34.9%), and Malaysia (22.7%) [14-17]. The discrepancies might be due to differences in the community awareness creation through mass media and social media. Further, in our study, more than half of the participants had negative attitude towards COVID-19 and its preventive measures, which is higher than the findings of studies conducted in Southern Ethiopia [15, 18] and lower than study done among Dessie and Kombolcha town residents in Ethiopia [19]. The discrepancy in the findings may be due to differences in the study period. The later studies were conducted earlier in the pandemic when the declaration and enforcement of state of emergency and other measures were still in place. Our findings show a significant decrease in the community's attitude towards COVID-19 and its prevention measures which can lead people to become discouraged to consistently adhere to the measures set forth by the government and the World Health Organization. These findings of the study have an implication on the public health and underscore the need for urgent concerted efforts to consistently promote the knowledge of the public in Ethiopia towards COVID-19 preventive measures, including COVID vaccination. If the current trend evidenced by this study continues in Ethiopia, COVID-19 will pose a

devastating outcome on the medical, financial and social aspect of citizens besides the potentialfor new strains of disease developing.

As COVID-19 continues to ravage the world, vaccination offers the most reliable hope for a permanent solution to controlling the pandemic. However, a vaccine must be accepted and used by a large majority of the population to create herd immunity [20]. The findings of this study showed that about one out of five participants are not willing to receive COVID-19 vaccine when it is available, which is higher than the findings reported from developed countries such as UK (3%) [6 21, 22]. The discrepancies might be due to insufficient knowledge about the vaccine and difference in the perception of the seriousness of the pandemic. This implies that if the doubts and fears of the majority regarding the vaccine are not addressed properly, we may not be able to attain herd immunity. Surprisingly, the finding of this study was lower than a study conducted in the US (31%) and Nigeria (80%) [13, 20]. This might be due to difference in access to wide variety of conspiracy theories and doubts via internet.

Consistent to the study conducted in China [23], vaccine hesitancy was more likely among females as compared to males in our study. This could be due to higher exposure of males for different media as compared to females in Ethiopia. In the present study, increased likelihood of vaccine hesitancy was also indicated among those with negative attitude towards COVID-19 and its preventive measures. The qualitative aspects of this study also found that those participants who would not take the vaccine stated one of their reasons to be their lack of implicit trust in the government and in health professionals. Thus, this lack of confidence in the government exhibited by 41.8% of our participants may be a potential hurdle we might face during the vaccination programs in Ethiopia.

Page 15 of 34

BMJ Open

In our study, those participants who received their information from social media (internet) were more likely to have vaccine hesitancy as compared to those who got their information from mass media (TV/radio). This finding of the study is in line with a study conducted to assess health protective behaviors and conspiracy theories during the pandemic, which has found a significant association between holding conspiracy beliefs and checking social media for news of COVID-19 [24]. This finding of the study is justified by our findings on both the quantitative and qualitative aspects of our study, which revealed the predominant reasons given for vaccine hesitancy were associated with the participant's beliefs in the conspiracy theories. Thus, the spread of these conspiracy theories is a potential issue that needs attention during vaccination campaigns. It is critical to explicitly explain the details of the COVID vaccines including its effectiveness, safety and quality to address the information need of the community. This study is the first community-based study to assess the Ethiopian community's perception

towards COVID-19 vaccine and its level of acceptance. We employed a mixed-methods design which enables us to make the deep understanding of the issue. However, the study might be limited due to social desirability bias during the data collection. However, to minimize this bias, the purpose of the study and assurance of the participant's anonymity were described to the participants prior to the administration of the interview. In addition to this, our sample overrepresents female population because the majority of the study participants that were found at home during data collection time were housewives. Furthermore, the study was conducted in only one sub-city. Therefore, generalization of the study results needs to be cautious.

Conclusions

A considerable proportion of the study participants in Addis Ababa have concerns on the COVID-19 vaccines and unwilling to accept them. This was mainly due to the prevailing misconceptions, negative attitudes, and use of social media as their primary source of information. Several conspiracy theories were put forth to justify their stance and this was mainly due to the misconceptions distributed from the use of social media as primary source of information about the vaccines. These findings of the study underscore the need to use social-media to disseminate reliable information regarding COVID-19 vaccination and the preventive measures, rather than only focusing on the mass-media messages. Overall, providing the community with health education and consistent government efforts in uphold the prevention measures are of paramount importance to tackle this pandemic.

Liezoni

280 List of Abbreviations

281 aOR: Adjusted Odds Ratio

- 282 CI: Confidence Interval
- 283 COR: Crude Odds Ratio
- 284 SARS: Severe Acute Respiratory Syndrome
- 285 UK: United Kingdom
 - 286 US: United States

| 1 | | |
|----------|-----|---|
| 2 | | |
| 3 4 | 287 | Declarations |
| 5 | | |
| 6 | 288 | Consent for nublication |
| 7 | 200 | Consent for publication |
| 8 | 289 | Not applicable |
| 9 10 | 205 | |
| 11 | | |
| 12 | 290 | Availability of data and material |
| 13 | | |
| 14 | 291 | Data are available upon reasonable request from the corresponding author. |
| 15 16 | | |
| 10 | 202 | Compating interests |
| 18 | 292 | Competing interests |
| 19 | 202 | The authors declare that they have no competing interests |
| 20 | 293 | |
| 21 | | |
| 22 | 294 | Authors Contributions |
| 24 | | |
| 25 | 295 | N.D., A.T., B.T., and D.A. conceptualized the study, designed the methodology, analyzed the |
| 26 | | |
| 27 | 296 | data, interpreted the results and drafted the initial manuscript and approved the final manuscript. |
| 20 | | |
| 30 | 297 | H.A., N.T., S.G., T.B., and Y.L. conceptualized the study, visualized the data, involved in data |
| 31 | | |
| 32 | 298 | analysis and interpretation and approved the final manuscript. All authors have read and |
| 33 34 | 200 | |
| 35 | 299 | approved the manuscript. |
| 36 | | |
| 37 | 300 | Acknowledgements |
| 38 | | |
| 39 40 | 301 | The authors would like to thank Myungsung Medical College for providing fund to conduct this |
| 41 | | |
| 42 | 302 | study. The authors are grateful to the study participants for their contributions. |
| 43 | | |
| 44 45 | 202 | Ethios annuaval statement |
| 46 | 303 | Etines approval statement |
| 47 | 204 | Ethical approval of this study was obtained from the Institutional Daview Reard (IDP) of |
| 48 | 504 | Ethical approval of this study was obtained from the institutional Review Board (IRB) of |
| 49 | 305 | Myungsung Medical College (MMC/IRB/067/21). The participants of the study were informed |
| 50 51 | 303 | ingungsung wedear conege (wivie/ikb/00//21). The participants of the study were informed |
| 52 | 306 | about the purpose of the study and provided their written consent. At the end of the interview |
| 53 | 500 | accut the purpose of the stady and provided then written consent. It the end of the interview, |
| 54 | 307 | the data collectors have provided information regarding the COVID-19 vaccines. |
| 55 56 | | |
| 50 57 | | |
| 58 | | 16 |

| 3 4 | 308 | Refe | rence |
|----------------|-----|------|--|
| 5 6 7 | 309 | 1. | World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 82. |
| 7 8 9 | 310 | | 2020. |
| 10 11 | 311 | 2. | COVID C. Global Cases by the Center for Systems Science and Engineering (CSSE) at |
| 12 13 | 312 | | Johns Hopkins University (JHU). JHU COVID-19 Resource Center. Johns Hopkins |
| 15 16 | 313 | | Coronavirus Resource Center. 2020. |
| 17 18 | 314 | 3. | Ranney ML, Griffeth V, Jha AK. Critical supply shortages-the need for ventilators and |
| 19 20 21 | 315 | | personal protective equipment during the Covid-19 pandemic. New England Journal of |
| 21 22 23 | 316 | | Medicine. 2020;382(18):e41. |
| 24 25 | 317 | 4. | Worldometer. Coronavirus Update (Live): Cases and Deaths from COVID-19 Virus |
| 26 27 | 318 | | Pandemic 2021 [cited 2021 Feb 24]. Available from: |
| 28 29 30 | 319 | | https://www.worldometers.info/coronavirus/. |
| 31 32 | 320 | 5. | Zikargae MH. COVID-19 in Ethiopia: Assessment of How the Ethiopian Government |
| 33 34 | 321 | | has Executed Administrative Actions and Managed Risk Communications and |
| 35 36 37 | 322 | | Community Engagement. Risk management and healthcare policy. 2020;13:2803. |
| 38 39 | 323 | 6. | Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views |
| 40 41 | 324 | | on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. |
| 42 43 | 325 | | Vaccine. 2020;38(49):7789-98. |
| 44 45 46 | 326 | 7. | Reuben RC, Danladi MM, Saleh DA, Ejembi PE. Knowledge, attitudes and practices |
| 47 48 | 327 | | towards COVID-19: an epidemiological survey in North-Central Nigeria. Journal of |
| 49 50 | 328 | | community health. 2020:1-14. |
| 51 52 53 | | | |
| 54 | | | |
| 55 56 | | | |
| סכ 57 | | | |

60

BMJ Open

| 1 2 | | | |
|----------------|-----|-----|--|
| 2 3 4 | 329 | 8. | Graffigna G, Palamenghi L, Boccia S, Barello S. Relationship between citizens' health |
| 5 6 | 330 | | engagement and intention to take the covid-19 vaccine in italy: A mediation analysis. |
| 7 8 0 | 331 | | Vaccines. 2020;8(4):576. |
| 9 10 11 | 332 | 9. | Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, Yaseen A, |
| 12 13 | 333 | | Ababneh NA, Bakri FG, Mahafzah A. High Rates of COVID-19 Vaccine Hesitancy and |
| 14 15 | 334 | | Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other |
| 16 17 18 | 335 | | Arab Countries. Vaccines. 2021; 9(1):42. https://doi.org/10.3390/vaccines9010042 |
| 19 20 | 336 | 10. | Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of |
| 21 22 | 337 | | Vaccine Acceptance Rates. Vaccines (Basel). 2021;9(2):160. Published 2021 Feb 16. |
| 23 24 | 338 | | doi:10.3390/vaccines9020160 |
| 25 26 27 | 339 | 11. | Sarasty O, Carpio CE, Hudson D, Guerrero-Ochoa PA, Borja I. The demand for a |
| 28 29 | 340 | | COVID-19 vaccine in Ecuador. Vaccine. 2020;38(51):8090-8098. |
| 30 31 | 341 | | doi:10.1016/j.vaccine.2020.11.013 |
| 32 33 | 342 | 12. | Ma L, Liu H, Tao Z, Jiang N, Wang S, Jiang X. Knowledge, Beliefs/Attitudes, and |
| 34 35 36 | 343 | | practices of rural residents in the prevention and control of COVID-19: an online |
| 37 38 | 344 | | questionnaire survey. The American journal of tropical medicine and hygiene. |
| 39 40 | 345 | | 2020;103(6):2357-67. |
| 41 42 43 | 346 | 13. | Enitan S, Oyekale A, Akele R, Olawuyi K, Olabisi E, Nwankiti A. Assessment of |
| 44 45 | 347 | | Knowledge, Perception and Readiness of Nigerians to participate in the COVID-19 |
| 46 47 | 348 | | Vaccine Trial. International Journal of Vaccines and Immunization. 2020;4:1-13. |
| 48 49 50 | 349 | 14. | Aweke Z, Jemal B, Mola S, Hussen R. Knowledge of COVID-19 and its prevention |
| 50 51 52 | 350 | | among residents of the Gedeo zone, South Ethiopia. Sources of information as a factor. |
| 53 54 | 351 | | Current Medical Research and Opinion. 2020;36(12):1955-60. |
| 55 56 | | | |
| 57 58 | | | 18 |

| 252 | 15 | Nimeria TE Amerika NDI Kanadada attituda and ana tina tamanda ana idalo amerika |
|-----|--|---|
| 352 | 15. | Nigussie IF, Azmach NN. Knowledge, attitude and practice towards covid-19 among |
| 353 | | Arba Minch town, southern Ethiopia. GSJ. 2020;8(6). |
| 354 | 16. | Nkansah C, Serwaa D, Adarkwah LA, Osei-Boakye F, Mensah K, Tetteh P, et al. Novel |
| 355 | | coronavirus disease 2019: knowledge, practice and preparedness: a survey of healthcare |
| 356 | | workers in the Offinso-North District, Ghana. The Pan African Medical Journal. |
| 357 | | 2020;35(79). |
| 358 | 17. | Mohamad EM, Azlan AA, Hamzah MR, Tham JS, Ayub SH. Public knowledge, |
| 359 | | attitudes and practices towards COVID-19: A cross-sectional study in Malaysia. |
| 360 | | medRxiv. 2020. |
| 361 | 18. | Mola S, Aweke Z, Jemal B, Hussein R, Hailu S, Neme D, et al. Magnitude and |
| 362 | | associated factors for attitude and practice of Southern Ethiopian residents toward |
| 363 | | COVID-19 and its preventions: A community based cross sectional study. 2020. |
| 364 | 19. | Kassa AM, Mekonen AM, Yesuf KA, Tadesse AW, Bogale GG. Knowledge level and |
| 365 | | factors influencing prevention of COVID-19 pandemic among residents of Dessie and |
| 366 | | Kombolcha City administrations, North-East Ethiopia: a population-based cross- |
| 367 | | sectional study. BMJ open. 2020;10(11):e044202. |
| 368 | 20. | Pogue K, Jensen JL, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, et al. Influences |
| 369 | | on attitudes regarding potential COVID-19 vaccination in the United States. Vaccines. |
| 370 | | 2020;8(4):582. |
| 371 | 21. | Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Acceptance of |
| 372 | | a COVID-19 vaccine in southeast Asia: A cross-sectional study in Indonesia. Frontiers |
| 373 | | in public health. 2020;8. |
| | | |
| | | |
| | | 10 |
| | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |
| | 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 | 35215.35316.35516.35517.35717.35917.36018.36118.36219.36319.36520.36820.36937037121.373 |

BMJ Open

| 2 | | | | |
|----------------------|-----|--------|---|------------|
| 3 4 | 374 | 22. | Salali GD, Uysal MS. COVID-19 vaccine hesitancy is associated with beliefs on | the |
| 5 6 | 375 | | origin of the novel coronavirus in the UK and Turkey. Psychological medicine. 2024 | 0:1- |
| 7 8 | 376 | | 3. | |
| 9 10 11 | 377 | 23. | Wang J, Jing R, Lai X, Zhang H, Lyu Y, Knoll MD, et al. Acceptance of COVID |)-19 |
| 12 13 | 378 | | Vaccination during the COVID-19 Pandemic in China. Vaccines. 2020;8(3):482. | |
| 14 15 | 379 | 24. | Allington D, Duffy B, Wessely S, Dhavan N, Rubin J. Health-protective behavior | our, |
| 16 17 18 | 380 | | social media usage and conspiracy belief during the COVID-19 public he | alth |
| 19 20 | 381 | | emergency. Psychological medicine. 2020:1-7. | |
| 21 22 23 | 382 | | | |
| 24 25 26 27 | 383 | Figur | e captions | |
| 28 | 384 | Figure | 1: Reasons of participants for refusing COVID-19 vaccination in Addis Ababa, Ethiopia | |
| 30 | 385 | | | |
| 31 32 | | | | |
| 33 | | | | |
| 34 35 | | | | |
| 36 | | | | |
| 37 38 | | | | |
| 39 | | | | |
| 40 41 | | | | |
| 42 | | | | |
| 43 | | | | |
| 44 45 | | | | |
| 46 | | | | |
| 47 | | | | |
| 48 40 | | | | |
| 49 50 | | | | |
| 51 | | | | |
| 52 | | | | |
| 53 54 | | | | |
| 55 | | | | |
| 56 | | | | |
| 57 | | | | . - |
| 58 59 | | | | 20 |
| | | | | |

60

| | | Frequency (N) | Percent (% |
|----------------|----------------------|---------------|------------|
| Sex | Male | 115 | 28.1% |
| | Female | 294 | 71.9% |
| Age | 18-29 | 174 | 42.5% |
| | 30-40 | 147 | 35.9% |
| | 41-50 | 40 | 9.8% |
| | >50 | 48 | 11.7% |
| Marital status | Not married | 123 | 30.1% |
| | Married | 255 | 62.3% |
| | Widowed | 20 | 4.9% |
| | Divorced | 11 | 2.7% |
| Religion | Christian | 349 | 85.3% |
| | Muslim | 60 | 14.7% |
| Educational | No formal education | 39 | 9.5% |
| status | Primary school | 105 | 25.7% |
| | Secondary and above | 265 | 64.8% |
| Occupation | Unemployed/housewife | 190 | 46.5% |
| | Employed | 219 | 53.5% |
| Monthly | ≤3200 ETB (≤100 USD) | 175 | 42.8% |
| income* | >3200 ETB (>100 USD) | 228 | 57.2% |

386Table 1: Socio-demographic characteristics of the study participants

BMJ Open

| Variables | Vaccine | hesitancy | cOR (95% CI) | aOR(95% CI) | |
|--------------------|------------|-------------|------------------|------------------|---|
| | Yes (%) | No (%) | | | |
| Sex | | | | | |
| Male | 17 (21.8%) | 98 (29.6%) | 1.00 | 1.00 | |
| Female | 61 (78.2%) | 233 (70.4%) | 1.49 (0.83-2.69) | 1.97 (1.10-3.89) | 0 |
| Age | | | | | |
| 18-29 | 34 (43.6%) | 140 (42.3%) | 1.00 | 1.00 | |
| 30-40 | 24 (30.8%) | 122 (36.9%) | 0.81 (0.46-1.44) | 1.03 (0.55-1.92) | (|
| 41-50 | 12 (15.4%) | 29 (8.8%) | 1.77 (0.82-3.82) | 2.22 (0.94-5.21) | (|
| >50 | 8 (10.2%) | 40 (12.0%) | 0.82 (0.35-1.92) | 1.08 (0.39-2.97) | (|
| Religion | | 7 | • | | |
| Christian | 8 (10.3%) | 52 (15.7%) | 1.00 | 1.00 | |
| Muslim | 70 (89.7%) | 278 (84.3%) | 1.64 (0.74-3.60) | 1.23 (0.54-2.83) | (|
| Educational status | | | | | |
| No formal | 9 (11.5%) | 30 (9.1%) | 1.11 (0.50-2.48) | 1.11 (0.39-3.16) | 0 |
| education | | | | | |
| Primary education | 13 (16.7%) | 93 (28.1%) | 0.53 (0.27-1.01) | 0.81 (0.40-1.63) | (|
| Secondary and | 56 71.8%) | 208 (62.8%) | 1.00 | 1.00 | |
| above | | | | | |
| Attitude | | | | | |
| Positive attitude | 28 (35 9%) | 169 (51 1%) | 1.00 | 1.00 | |

| | Negative attitude | 50 (64.1%) | 162 (48.9%) | 1.87 (1.12-3.12) | 1.75 (1.08-3.02) | 0.04 |
|-----|---------------------|-------------------------|------------------|-----------------------|------------------|--------|
| | Primary source of i | nformation | | | | |
| | TV/Radio | 38 (48.7%) | 255 (77.0%) | 1.00 | 1.00 | |
| | Social media | 40 (51.3%) | 76 (23.0%) | 3.53 (1.67-6.98) | 3.59 (1.75-7.37) | 0.0001 |
| | (internet) | | | | | |
| 390 | cOR: Crude Odds Rat | io | aOR: A | djusted Odds Ratio | | |
| 391 | | | | | | |
| 392 | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | 22 |
| | F . | an marile second second | | | in a subtract | 23 |
| | For pe | er review only - htt | p://bmJopen.bmj. | com/site/about/guidel | ines.xntml | |



Figure 1: Reasons of participants for refusing COVID-19 vaccination in Addis Ababa, Ethiopia

215x279mm (102 x 100 DPI)

Questionnaire (English Version)

| 1 | Gender: | 1. Male |
|---|-----------------------|---|
| | | 2. Female |
| 2 | Age | in years |
| 3 | Marital status | 1. Single |
| | | 2. Married |
| | | 3. Widowed |
| | 0 | 4. Divorced |
| 1 | Educational status | 1. illiterate |
| | A | 2. can read and write |
| | | $3. 1-8^{\text{th}}$ grade |
| | | $4 9-12^{\text{th}} \text{ grade}$ |
| | | 5 Technique |
| | | 6 Higher education |
| 5 | Religion | 1 Christian |
| | Tengron | 2 Muslim |
| | | 2. Mushini 2. Other |
| | Occupation | 3. Other |
| | Occupation | 1. Merchant 2. Gov't employee |
| | | 3. Private employee |
| | | 4. House wife |
| | | 5. Daily laborer |
| | | 6. Police/ Solidier |
| | | 7. Unemployed |
| | | 8. janitor |
| | | 9. student |
| | | 10. Other |
| 5 | Family monthly income | 1 <1650 ETB |
| - | | 2. $1651 - 3200$ ETB |
| | | 3 3201 - 5800 FTB |
| | | 4 5801 - 7800 FTB |
| | | $\begin{array}{c} +. 5001 - 7000 \text{ ETD} \\ 5 7001 - 10400 \text{ ETD} \end{array}$ |
| | | $\begin{array}{c} J. /001 = 10400 \text{ ETD} \\ (\) 10400 \text{ ETD} \end{array}$ |
| | | 6. >10400 E1B |

| | What is the source of your information about COVID-19 | Social media (SNS) TV/Radio (New Media) Religious leaders Friends/ Family/ Neighbors Directly from healthcare workers Others |
|---|--|--|
| С | . Knowledge (please tick what is/are applicable) | |
| 1 | Mode of transmission: | Respiratory droplets Airborne Fecal-Oral route Blood transmission Contact with contaminated surfaces Contact with a COVID-19 positive patient Skin contact Breast milk Vertical transmission |
| 2 | Symptoms (that can be expected from a Covid-19 patient) | Fever Muscle pain Fatigue Diarrhea Sneezing Loss of smell Vomiting Runny nose Shortness of Breath Cough Loss of taste Stuffy nose Stuffy nose Conjunctivitis Skin rash No symptom |
| 3 | Are asymptomatic patients capable of transmitting the disease? | 1. Yes 2. No |

| 4 | Which group of population has likelihood of | 1. Elderly |
|----|--|--|
| | developing severe disease? (please tick | 2. Pregnant women |
| | what is/are applicable) | 3. Children |
| | | 4. Smoker |
| | | 5. People with co-morbid (DM, HTN, asthma) |
| | | conditions |
| | | 6. Obesity |
| | | 7. I don't know |
| 5 | Prevention methods: Are you aware of that | 1. Yes |
| | hand washing is one of the primary methods | 2. No |
| | of preventing COVID-19 infection? | |
| 6 | What is/are the preferable methods of | 1. Hand wash with soap & water |
| | preventing COVID-19 transmission? | 2. Hand wash with water only |
| | | 3. Use of hand sanitizers |
| | | |
| 7 | Duration of handwashing (minimum | 1. 10 seconds |
| | duration): | 2. 20 seconds |
| | | 3. 30 seconds |
| | | 4. 40 seconds |
| | | 5. I don't know |
| | | 5 |
| 8 | Do you think use of face masks can prevent | 1. Yes |
| | COVID-19 transmission? | 2. No |
| 9 | Do you think double-mask use is effective | 1. Yes |
| | in prevention? | 2. No |
| 10 | What is the recommended minimum distance | 1. <2 meter |
| | to maintain adequate social distancing? | 2. >2 meter |
| | | 3. I don't know |
| 11 | In order to prevent spread, do you think | 1. Yes |
| | individuals should avoid going to crowded | 2. No |
| | places and taking public transportation? | |
| 12 | Do you think you should stop to maintain | 1. Yes |
| | social distancing if you are wearing a mask? | 2. No |
| 12 | Do you think you should avoid shaking | 1. Yes |
| 15 | | |

| 14 | Provided that your family member is COVID-19 positive, would you put yourself in self-quarantine? | 1. Yes 2. No |
|----|---|-----------------|
| 15 | How long should people in contact with COVID-19 positive put into self- quarantine? | () |

| D. A | ttitude | | |
|------|--|----|-----|
| 1 | Do you agree that COVID-19 will be successfully controlled? | 1. | Yes |
| | | 2. | No |
| 2 | I have no concern of being infected with COVID-19 | 1. | Yes |
| | | 2. | No |
| 3 | Do you have confidence that Ethiopia will win the battle | 1. | Yes |
| | against COVID-19? | 2. | No |
| 4 | Is the Ethiopian government handling the COVID-19 health | 1. | Yes |
| | crisis well? | 2. | No |
| | | | |
| 5 | Do you think that wearing a face mask will effectively prevent | 1. | Yes |
| | COVID-19? | 2. | No |
| | | | |
| 6 | Do you think that adequate social distancing will effectively | 1. | Yes |
| | prevent COVID-19? | 2. | No |
| 7 | Do you think washing hands with soup and water helps to | 1. | Yes |
| | prevent COVID-19? | 2. | No |
| | - | | |
| 8 | Would you be willing to tell people if you were having | 1. | Yes |
| | COVID-19 symptoms? | 2. | No |
| 9 | Would you inform the health authorities if a family member | 1. | Yes |
| | exhibits the symptoms? | 2. | No |
| | | | |
| 10 | Do you think traditional medicine can prevent or treat COVID- | 1. | Yes |
| | 19? | 2. | No |
| 11 | Do you think COVID-19 doesn't affect youngsters? | 1. | Yes |
| | | 2 | No |

| | | 1 | |
|----|---|----|--|
| 1 | In recent days have you worn a mask leaving | 1. | Always |
| | home? | 2. | Sometimes |
| | | 3. | Never |
| 2 | Do you wash your hands before putting your | 1. | Yes |
| | mask on? | 2. | No |
| 3 | What kind of mask do you use? | 1. | surgical |
| | | 2. | N-95 |
| | | 3. | cloth |
| 4 | If cloth, how often do you wash and reuse it? | 1. | Everyday |
| | | 2. | Weekly |
| | | 3. | monthly |
| 5 | -If surgical mask, how often do you change? | 1. | Everyday |
| | | 2. | Weekly |
| | | 3. | monthly |
| 6 | If you reuse a mask, where/ how do you store | 1. | In the pocket |
| | it? | 2. | plastic bag |
| | | 3. | Holding on hands |
| 7 | Do you touch your face while wearing a mask? | 1. | Always |
| • | | 2. | Sometimes |
| | | 3. | Never |
| 8 | Do you avoid touching your mask? | 1. | Yes |
| | | 2. | No |
| 9 | How do you take off your mask? | 1. | from the front of mask |
| | | 2. | from the string of mask |
| 10 | How do you greet your friends? | 1. | hand shake |
| | | 2. | hugging |
| | | 3. | elbow touching |
| | | 4. | waving hand/without contact |
| 11 | In recent days have you practiced maintain | 1. | Yes |
| | your distance at 2m? | 2. | No |
| 12 | When do you wash your hands? | 1. | After I touch dirty materials such as Bi |
| | | | door handles |
| | | 2. | After I touch my nose or ears or skin |
| | | | parts |

| | 3. Before putting on a mask and after taking |
|--|--|
| | off a mask |
| | 4. After coughing and sneezing into hands |
| | 5. When entering and leaving a public place |

| 6 | |
|----------|--|
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 10 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 22 | |
| 22 | |
| 24 25 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | |
| 31 | |
| 25 | |
| 22 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | |
| 40 | |
| 41 | |
| 42 | |
| 43 | |
| 44 | |
| 45 | |
| 75 16 | |
| 40 | |
| 4/ | |
| 48 | |
| 49 | |
| 50 | |
| 51 | |
| 52 | |
| 53 | |
| 54 | |
| 55 | |
| 56 | |
| 50 | |
| 5/ | |
| 58 | |
| 59 | |
| 60 | |

| 1 | Have you heard about any prospective | 1. | Yes |
|---|---|----------|--|
| | COVID-19 vaccine? | 2. | No |
| 2 | If yes, where did you get the information | 1. | Internet/social media |
| | from? | 2. | Mass media (Television, radio) |
| | | 3. | Newspapers |
| | | 4. | Other sources |
| | 9 | If othe | er sources, specify () |
| 3 | Will you get vaccinated, if possible? | 1. | Yes |
| | | 2. | No |
| | | 3. | Not sure |
| 4 | If no, why? | 1. | The vaccine itself might cause the infection |
| | | 2. | I'm worried about the side effects |
| | | 3. | I believe it will be used as a biological |
| | | | weapon to serve those who produce vaccine |
| | | 4. | I don't find it reliable as it took a short time to get developed |
| | | 5. | I don't think the vaccines produced will be |
| | | | effective |
| | | 6. | I don't think I have enough information about the vaccines |
| | | 7. | I believe COVID-19 is exaggerated, it is not a |
| | | Q | I profor other ways of protection |
| | | 0. 0 | In general I have doubts about the vaccine |
| | | 9. 10 | . Other |
| 5 | Should children be vaccinated too? | 1 | Vac |
| 5 | | 1. 2 | No |

| 6 | If the answer is no, explain why? | |
|---|-----------------------------------|--|
|---|-----------------------------------|--|

Questions for the in-depth interview

- 1. How do you know about COVID-19? (Probe: transmission mechanisms, prevention strategies, vaccines availability, perceptions towards the vaccines)
- 2. What were your initial reactions towards COVID-19 when you first heard about it? How about now?
- 3. What are your thoughts on the COVID-19 vaccine? (Probe: availability, efficacy, perceptions on quality, side effects)
- 4. What factors do you think will hinder people from receiving COVID-19 vaccines?

SRQR Reporting checklist for qualitative study

| | Reporting item | Page |
|---|--|----------|
| | | number |
| Title | | 1 |
| | Concise description of the nature and topic of the study identifying the study as qualitative or indicating the approach (e.g. ethnography, grounded theory) or data collection methods (e.g. interview, focus group) is recommended | Title |
| Abstract | | |
| | Summary of the key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results and conclusions | Abstract |
| Introduction | | |
| Problem formulation | Description and significance of the problem / phenomenon studied: review of relevant theory and empirical work; problem statement | Page # 4 |
| Purpose or research question | Purpose of the study and specific objectives or questions | Page # 5 |
| Methods | | <u> </u> |
| Qualitative approach and research paradigm | Qualitative approach (e.g. ethnography, grounded theory, case study, 1henomenology, narrative research) and guiding theory if appropriate; identifying the research paradigm (e.g. postpositivist, constructivist / interpretivist) is also recommended; rationale. The rationale should briefly discuss the justification for choosing that theory, approach, method or technique rather than other options available; the assumptions and limitations implicit in those choices and how those choices influence study conclusions and transferability. As appropriate the rationale for several items might be discussed together. | Page # 5 |
| Researcher characteristics and reflexivity | Researchers' characteristics that may influence the research, including personal attributes, qualifications / experience, relationship with participants, assumptions and / or presuppositions; potential or actual interaction between | Page # 5 |

| 2 | |
|------------|--|
| 3 | |
| 4 | |
| 5 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| ۵. | |
| 10 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 11 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 10 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 20 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 22 | |
| 22 | |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 20 | |
| 38 | |
| 39 | |
| 40 | |
| 41 | |
| <u>⊿</u> ว | |
| 42 | |
| 43 | |
| 44 | |
| 45 | |
| 46 | |
| 10 | |
| 4/ | |
| 48 | |
| 49 | |
| 50 | |
| 51 | |
| 51 | |
| 52 | |
| 53 | |
| 54 | |
| 55 | |
| 55 | |
| 00 | |
| 57 | |
| 58 | |
| 59 | |
| 60 | |
| 00 | |

| | researchers' characteristics and the research questions, approach, methods, results and / or transferability | |
|--|--|---------------|
| Context | Setting / site and salient contextual factors; rationale | Page # 5 |
| Sampling strategy | How and why research participants, documents, or events were selected; criteria for deciding when no further sampling was necessary (e.g. sampling saturation); rationale | Page # 6 |
| Ethical issues pertaining to human | Documentation of approval by an appropriate ethics review board and participant consent, or explanation | Page # 7 |
| subjects | for lack thereof; other confidentiality and data security issues | |
| Data collection methods | Types of data collected; details of data collection procedures including (as appropriate) start and stop dates of data collection and analysis, iterative process, triangulation of sources / methods, and modification of procedures in response to evolving study findings; rationale | Page # 6 |
| Data collection instruments and technologies | Description of instruments (e.g. interview guides, questionnaires) and devices (e.g. audio recorders) used for data collection; if / how the instruments(s) changed over the course of the study | Page # 6 |
| Units of study | Number and relevant characteristics of participants, documents, or events included in the study; level of participation (could be reported in results) | Page # 5 |
| Data processing | Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymisation / deidentification of excerpts | Page # 7 |
| Data analysis | Process by which inferences, themes, etc. were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale | Page # 7 |
| Techniques to enhance | Techniques to enhance trustworthiness and credibility of data analysis (e.g. member checking, audit trail, | Page # 7 |
| trustworthiness | triangulation); rationale | |
| Results/findings | | Dec. 11.0 |
| Syntheses and interpretation | Main findings (e.g. interpretations, interences, and themes); might include development of a theory or model, or integration with prior research or theory | Page # 8 - 10 |
| Links to empirical data | Evidence (e.g. quotes, field notes, text excerpts, photographs) | Page # 8 - 10 |
| | · | |

| | to substantiate analytic findings | |
|-----------------------|--|-----------|
| Discussion | | |
| Integration with | Short summary of main findings; explanation of how | Page # 11 |
| prior work, | findings and conclusions connect to, support, | 13 |
| implications, | elaborate on, or challenge conclusions of earlier | |
| transferability and | scholarship; discussion of scope of application / | |
| contribution(s) to | generalizability; identification of unique | |
| the field | contributions(s) to scholarship in a discipline or field | |
| Limitations | Trustworthiness and limitations of findings | Page # 13 |
| Other | | |
| Conflicts of interest | Potential sources of influence of perceived influence | Page # 3 |
| | on study conduct and conclusions; how these were | |
| | managed | |
| Funding | Sources of funding and other support; role of funders | Page # 3 |
| | in data collection, interpretation and reporting | |

in data collection, interpretation and reporting